What Is Peritoneal Carcinomatosis and How Is It Treated?

Peritoneal carcinomatosis is a condition in which cancer spreads to the peritoneum, the thin membrane lining the abdominal cavity and covering most of the organs inside it. It typically develops when tumor cells shed from a primary cancer elsewhere in the abdomen, seed the peritoneal surfaces, and grow into new deposits. For decades this was considered a terminal diagnosis with few treatment options, but a shift in thinking toward treating it as a regional disease rather than a widespread systemic one has opened the door to aggressive surgical and chemotherapy combinations that can extend survival by years in selected patients.

How Cancer Reaches the Peritoneum

The process starts with tumor cells breaking free from a primary cancer, either individually or in clumps. Once loose in the abdominal cavity, these cells travel along the natural flow of peritoneal fluid, which constantly circulates to lubricate abdominal organs. They eventually land on distant peritoneal surfaces, attach, and invade the tissue beneath the membrane. Once embedded, new blood vessels grow to feed the deposits, sustaining further tumor growth and enabling additional spread.¹

This pattern means peritoneal deposits tend to accumulate in predictable locations: the spaces around the liver, the lining of the pelvis, the surface of the bowel, and the omentum (the fatty apron that drapes over the intestines). Gravity and fluid dynamics play a role. Areas where fluid naturally pools or slows down tend to collect more tumor cells. Surgery, biopsies, or even the act of the primary tumor perforating through the wall of an organ can accelerate this seeding process.

Which Cancers Spread to the Peritoneum

Ovarian cancer is one of the most common sources, with a large proportion of patients already showing peritoneal involvement at diagnosis. Colorectal cancer is another major contributor, particularly tumors that penetrate the full thickness of the bowel wall. Gastric cancer, appendiceal tumors, and pancreatic cancer round out the most frequent origins. Less commonly, cancers of the bladder, uterus, or even the peritoneum itself (primary peritoneal cancer) can be responsible.

Appendiceal tumors deserve special mention because of a distinctive variant called pseudomyxoma peritonei. In this condition, a mucinous tumor of the appendix ruptures and gradually fills the abdominal cavity with gelatinous material containing neoplastic cells.² The abdomen can accumulate large volumes of this jelly-like substance, a phenomenon sometimes called “jelly belly.” Unlike typical peritoneal carcinomatosis, pseudomyxoma peritonei often grows slowly and tends to stay within the abdomen rather than spreading to distant organs, which makes it one of the more treatable forms of peritoneal disease if caught and managed at a specialized center.³

The biology of the primary tumor matters enormously for prognosis and treatment planning. In colorectal cancer, for instance, specific molecular subtypes influence how responsive peritoneal deposits will be to chemotherapy. There is growing evidence that one particular subtype shows relative resistance to oxaliplatin, a drug frequently used in heated intraperitoneal chemotherapy, which may partly explain why some trials have failed to show the expected survival benefits.⁴ For gastric cancer, patients with moderately differentiated disease and a low burden of peritoneal deposits appear to benefit more from aggressive treatment approaches.⁵

How It Is Detected and Staged

Peritoneal carcinomatosis can be frustratingly hard to catch early. Small deposits on the peritoneum often escape detection on routine CT scans, especially when they are flat or miliary (resembling tiny seeds rather than distinct lumps). Symptoms like bloating, early fullness after eating, vague abdominal discomfort, or unexplained weight changes are easily attributed to other causes. In many patients, the condition is discovered incidentally during surgery for the primary cancer or only after symptoms like bowel obstruction or accumulation of fluid (ascites) make the disease impossible to ignore.

CT scanning remains the standard first-line imaging tool. In ovarian cancer, CT has been shown to correctly identify peritoneal carcinomatosis in roughly nine out of ten patients, with sensitivity around 95% and specificity near 87%.⁶ Laparoscopy performed slightly better overall in the same study, particularly for detecting disease in the pelvis and on the surface of the small intestine, areas where CT tends to underperform.

Surgeons use a scoring system called the Peritoneal Cancer Index, or PCI, to quantify how extensively the disease has spread. The abdomen is divided into thirteen regions, and each region gets a score based on the size of the largest tumor deposit found there. The scores are added together, with a maximum of 39 indicating disease in every region. This number is critically important because it drives treatment decisions: a PCI above certain cutoffs, commonly 15 or 20 depending on the tumor type, often signals that complete surgical removal is unlikely to succeed. One challenge is that CT-based estimates of PCI tend to underestimate the true burden found at surgery.⁷ In one study of colorectal carcinomatosis patients, the radiologist’s median PCI estimate was 4, while the actual surgical finding was 7.5, a meaningful gap when treatment eligibility hangs on specific thresholds.

Researchers are working on AI-driven imaging tools to close this gap. A deep learning model combining radiomics (computational features extracted from CT images) with standard clinical data achieved an area under the curve above 0.85 for predicting occult peritoneal spread in pancreatic cancer, substantially outperforming clinical assessment alone.⁸ Tools like this could eventually help identify patients with hidden peritoneal disease before they undergo unnecessary exploratory surgeries.

Cytoreductive Surgery and HIPEC

The treatment that has most changed outcomes for peritoneal carcinomatosis is a combination of two procedures performed back to back: cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC). The surgical component aims to strip away or remove every visible tumor deposit in the abdomen, which can involve removing sections of the peritoneum itself (peritonectomy), portions of the bowel, the omentum, and sometimes the spleen or parts of other organs.⁹ The goal is to leave behind no macroscopic disease.

Immediately after the surgeon finishes, heated chemotherapy solution is circulated directly through the open abdominal cavity for about an hour. Heat serves multiple purposes: it kills cancer cells on its own, it enhances the killing power of certain chemotherapy drugs, and it increases how deeply those drugs penetrate into tissue.¹⁰ Temperature matters in a very specific way. Research has shown that temperatures above 40°C appear to be a critical threshold for amplifying the effect of drugs like cisplatin and doxorubicin, and patients whose abdominal cavities reached and maintained that temperature during HIPEC had better overall and progression-free survival than those who did not.¹¹

Delivering chemotherapy directly into the abdomen rather than intravenously exploits a key anatomical feature: the peritoneum acts as a partial barrier between the abdominal cavity and the bloodstream. When drugs are infused into the peritoneal space, they reach far higher local concentrations at the tumor sites than intravenous chemotherapy could achieve, because IV drugs struggle to cross that same barrier in the opposite direction.¹² The drugs also remain in the cavity longer, extending their half-life and contact time with microscopic residual disease.

How completely the surgeon removes visible disease is the single most important predictor of outcome. Surgeons grade this using a completeness-of-cytoreduction score. A score of CC-0 means no visible tumor remains; CC-1 means only deposits smaller than about 2.5 millimeters are left behind. Both are considered “complete” cytoreductions and are associated with the best survival outcomes.¹³ When larger residual disease is left, the benefit of HIPEC drops off sharply.

Risks and Complications of CRS/HIPEC

This is not a minor surgery. CRS/HIPEC routinely takes six to twelve hours, involves extensive tissue removal, and carries serious risks. In one large series, roughly one in seven patients (14.5%) required a reoperation in the early postoperative period, most commonly for wound breakdown, internal bleeding, or leaking surgical connections in the bowel. Bleeding complications tended to occur within the first five days, while wound and anastomotic problems peaked around days seven to nine. The overall in-hospital death rate was about 2%, but among those who needed reoperation, it rose to 10%.¹⁴

Given these risks, patient selection is critical. Fitness for surgery makes a measurable difference. A prehabilitation program involving exercise, nutrition optimization, and psychological support before surgery improved patients’ walking capacity by an average of about 42 meters on a six-minute walk test. More meaningfully, patients who could walk at least 360 meters after prehabilitation had significantly fewer serious postoperative complications. Failing to reach that threshold was an independent risk factor for complications, roughly quadrupling the odds.¹⁵

Quality of Life After Surgery

Patients and families understandably want to know what life looks like on the other side of such a grueling procedure. The short answer: it gets worse before it gets better, but most measures recover. In the first three months after CRS/HIPEC, physical function, pain levels, and overall quality-of-life scores drop significantly. Most of these rebound to baseline or better by six months.¹⁶ Emotional well-being, interestingly, improved within three months and stayed above baseline. This is a pattern commonly seen after major cancer surgeries: the psychological relief of having done something decisive about the disease outpaces physical recovery.

Longer-term data from pseudomyxoma peritonei patients showed that physical, role, and social function scores were impaired for up to twelve months but then normalized to levels comparable to the general population. Global health scores were not significantly different from reference populations at any point. However, some gastrointestinal symptoms persisted: constipation and diarrhea remained above normal levels even years after surgery, and cognitive function scores were slightly lower.¹⁷

In a long-term survivorship analysis with an average follow-up exceeding five years, patients who had undergone CRS/HIPEC scored as well as or better than the general population on generic quality-of-life measures. They actually reported better scores for emotional performance, mental health, social function, and pain. Gastrointestinal-specific assessments showed few or no persistent symptoms in most patients, though those who had required bowel resections reported somewhat more GI issues.¹⁸

PIPAC as an Alternative Delivery Method

Not every patient is a candidate for CRS/HIPEC, whether because the disease is too extensive, the patient is not fit enough for a marathon surgery, or the tumor type does not respond well to heated chemotherapy. Pressurized intraperitoneal aerosol chemotherapy, or PIPAC, is a newer approach designed to reach patients who fall outside the traditional surgical window. Instead of flooding the abdomen with heated liquid, PIPAC uses a laparoscopic procedure to spray an aerosolized mist of chemotherapy under pressure throughout the peritoneal cavity.¹⁹

The rationale rests on physics. The aerosol creates a thin film of microdroplets that coats the entire peritoneal surface more evenly than liquid delivery. The increased pressure inside the sealed abdomen counteracts the elevated pressure within tumors that normally pushes drugs back out, allowing deeper penetration into tumor tissue. PIPAC uses much lower drug doses than HIPEC yet achieves higher intraperitoneal drug concentrations.²⁰ Because it is a minimally invasive procedure, it can be repeated multiple times and can be combined with systemic chemotherapy running in parallel.

PIPAC is still considered investigational for most indications, and large randomized trials comparing it head-to-head with other approaches are ongoing. But for patients with unresectable disease or recurrence after prior treatment, it represents a genuinely different mechanism of drug delivery rather than just a repackaging of the same agents.

When Surgery Is Not an Option

For patients with advanced peritoneal carcinomatosis who are not candidates for curative-intent surgery, the disease trajectory often includes bowel obstruction, worsening ascites, malnutrition, and progressive pain. Palliative care becomes the central focus, and the decisions involved are genuinely difficult.

Bowel obstruction is one of the most common and distressing complications. When the peritoneal deposits compress or encase the intestines enough to block them, patients cannot eat, experience severe nausea and vomiting, and may develop dangerous distension. Palliative surgery to relieve the obstruction can restore the ability to eat and allow patients to go home, but the trade-offs are steep. Complication rates are high, re-obstruction requiring readmission is common, and a substantial portion of whatever survival time remains may be spent recovering from the operation itself.²¹ For patients whose cancer has already progressed through recent chemotherapy, comfort care without surgery is often the better choice.²²

Nonsurgical management of inoperable bowel obstruction typically involves medications to reduce nausea and intestinal secretions, pain control, and sometimes placement of a venting gastrostomy tube to drain fluid from the stomach and relieve pressure. A small prospective study of this approach showed complete resolution of nausea in all patients who completed the protocol, along with improvements in pain, constipation, oral intake, and bowel movements. The sobering reality: only two of fifteen patients in that study were alive at six months.²³

Emerging Research Frontiers

Several lines of investigation are actively trying to improve on current treatments. On the detection side, liquid biopsy of peritoneal fluid is showing promise as a way to monitor disease more precisely than traditional cytology. Measuring circulating tumor DNA (ctDNA) in peritoneal washings before and after HIPEC has proven to be a better indicator of peritoneal disease than standard cytology, and changes in ctDNA levels may help identify patients at high risk of relapse.²⁴ If validated in larger studies, this could allow clinicians to tailor follow-up intensity and catch recurrences earlier.

Immunotherapy is the other major frontier. The peritoneal cavity presents unique challenges for immune-based treatments because its microenvironment tends to suppress immune activity, but researchers are exploring multiple angles. CAR-T cells engineered to recognize carcinoembryonic antigen, a protein commonly found on colorectal and other gastrointestinal tumors, have shown the ability to suppress tumors when delivered directly into the peritoneal cavity in preclinical work. Combining these with immune checkpoint inhibitors appears to strengthen the response.²⁵ Vaccine-based approaches, natural killer cells, and various combinations with cytokines are also under investigation. None of these have reached routine clinical use for peritoneal carcinomatosis yet, but the logic of delivering immune therapies locally rather than systemically mirrors the same peritoneal-barrier advantage that makes HIPEC work.

Why the Primary Cancer Type Shapes Everything

One of the most important things to understand about peritoneal carcinomatosis is that it is not one disease with one prognosis. A patient with low-grade appendiceal mucinous disease and pseudomyxoma peritonei can live for many years after CRS/HIPEC, with quality-of-life scores that eventually match the general population. A patient with colorectal peritoneal metastases has a more guarded outlook, and one with gastric or pancreatic peritoneal disease faces the most challenging prognosis of all.

The conceptual shift that has driven treatment advances over the past three decades is the recognition that in the absence of liver or other distant metastases, peritoneal carcinomatosis behaves more like a loco-regional problem than a fully systemic one.²⁶ That distinction matters because loco-regional disease can be attacked with local tools, the same logic behind radiation for a brain metastasis or liver-directed therapy for hepatic tumors. But the distinction only holds when the disease truly is confined to the peritoneum. When it has already seeded distant organs, the rationale for extensive abdominal surgery weakens, and systemic approaches take priority. Accurate staging, ideally combining imaging with diagnostic laparoscopy, is what makes the difference between offering a patient a potentially curative operation and subjecting them to a massive surgery that will not change their trajectory.